Sobi (Swedish Orphan Biovitrum AB)

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Ingredients

Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Ingredients

Therapeutic for paroxysmal nocturnal haemoglobinuria: pegcetacoplan

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare and chronic blood disorder in which red blood cells are destroyed via extravascular and intravascular haemolysis
Finance

Sobi to acquire Synagis US rights from AstraZeneca

Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi’s expertise in paediatrics and immunology
Recruitment

Fredrik Wetterlundh joins Sobi
Pharmaceutical

Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel
Pharmaceutical

Norbert Oppitz joins Sobi as new Senior VP, Specialty Care
Finance

Sobi enters into new distribution agreement with Valeant for Ammonul

The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
Subscribe now